Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
Date:3/10/2010

se factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or a failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's Registration Statement declared effective by the SEC on August 10, 2009. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

    
    
    CUMBERLAND PHARMACEUTICALS INC.
    CONSOLIDATED BALANCE SHEETS
    DECEMBER 31, 2009 AND 2008
    
    ASSETS                                         2009              2008
                                                   ----              ----
    Current assets:
      Cash and cash equivalents                $78,701,682       $11,829,551
      Accounts receivable, net of allowances     6,176,585         3,129,347
      Inventories                                4,822,873         1,762,776
      Prepaid and other current assets           2,746,259           481,312
      Deferred tax assets                          726,196           507,212
                 Total current assets           93,173,595        17,710,198
    Property and equipment, net                    918,412           432,413
    Intangible assets, net                       7,956,009         8,528,732
    Deferred tax assets                          1,306,514         1,000,031
    Other assets                                   369,790    
'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Biosensors International Group, Ltd. ("Biosensors " or ... a developer, manufacturer and marketer of innovative medical devices, ... ("Q4 FY15") and fiscal full year ended 31 March ... , Q4 FY15: , Total revenue ... of Fiscal Year 2014 ("Q4 FY14") due to licensing ...
(Date:5/27/2015)... 27, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... , the company,s president and chief executive officer, will ... week in New York City.  The presentation, which will ... at 11:30 a.m. EDT. To access the ... to the Company,s website at http://www.pdl.com and ...
(Date:5/27/2015)... International, Inc. (NASDAQ: BDSI ) announced that Dr. Mark ... present at two important upcoming healthcare conferences: ... Time Grand Hyatt, New York City , ... Growth Stock Conference Tuesday, June 9 2:50 PM Central Time (3:50 ... , Dr. Sirgo will be discussing progress with ...
Breaking Medicine Technology:Biosensors Reports Financial Results for Fiscal Year 2015 2Biosensors Reports Financial Results for Fiscal Year 2015 3Biosensors Reports Financial Results for Fiscal Year 2015 4Biosensors Reports Financial Results for Fiscal Year 2015 5Biosensors Reports Financial Results for Fiscal Year 2015 6Biosensors Reports Financial Results for Fiscal Year 2015 7PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference and the William Blair Growth Stock Conference 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference and the William Blair Growth Stock Conference 3
... Inc., (IBI), a privately held biopharmaceutical company that ... ophthalmic pharmaceuticals, today announced that Wendy Yee Murahashi, ... as Vice-President, Clinical Development.  Dr. Murahashi will lead ... proprietary Verisome® drug delivery technology. ...
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and chief operating officer, is scheduled to present a ... in New York City on Wednesday, December 14th at ... http://photos.prnewswire.com/prnh/20030226/RIGLLOGO ) To access the live ...
Cached Medicine Technology:Icon Appoints Murahashi Vice President, Clinical Development 2
(Date:5/27/2015)... (PRWEB) May 27, 2015 Holly CaSaroll, founder ... on preventing burns, aging and cancer. The skin is the ... daily. Every year more than 3.5 million cases of skin ... percent are caused by the sun's ultraviolet rays (UVR). ... themselves. , 1. Avoid the sun between the ...
(Date:5/27/2015)... May 27, 2015 CRN International, the ... as its new Chief Financial Officer. , Prinner most ... prior to that held financial/operational executive positions at telecom ... Corp., Conversent Communications, Utilicom, and SNET. His accounting ... , At CRN, Prinner will be able to tap ...
(Date:5/27/2015)... Antonio, TX (PRWEB) May 27, 2015 ... “Pass The Torch” Addiction Treatment Scholarship Award. From June ... awarded $10,000 to 50 drug and alcohol addiction treatment ... afford treatment. Scholarships were drawn at random at addiction ... Director for Sky Toxicology, Matt Green said, “Sky Toxicology ...
(Date:5/27/2015)... NC (PRWEB) May 27, 2015 Danish ... “front line” biomarkers that have the potential to help ... here to read the full story that has ... Aalborg University in Aalborg, Denmark say new biomarkers found ... the outlook for patients with malignant mesothelioma . ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 With the ... Studios, editors can quickly and easily add filmic color grades ... CUBE LUT files. , FCPX LUT Cross Processed Plugin can ... to contemporary looks and everything in between. , FCPX LUT ... be used in many different softwares. With the FCPX LUT ...
Breaking Medicine News(10 mins):Health News:In Recognition of National Melanoma Awareness Month, Beauty Guru Details Skin Tips to Prevent Cancer and Premature Aging 2Health News:CRN International Names New Chief Financial Officer 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 2Health News:Sky Toxicology Reaches Their $500,000 Goal in Drug and Alcohol Addiction Treatment Patient Scholarship Awards 3Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release FCPX LUT Cross Processed Plugin for Final Cut Pro X 2
... race and/or marital status can factor into the overall ... is the most significant factor impacting overall survival, according ... Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC ... Cancer Institute, in 2008 approximately 215,020 new cases of ...
... small tissue samples from patients with lung cancer and ... is now being utilized to better tailor the chemotherapy ... cell lung cancer, according to a study presented at ... by ASTRO, ASCO, IASLC and the University of Chicago., ...
... chemotherapy agents with targeted therapies called monoclonal antibodies ... patients with advanced non-small cell lung cancer according ... Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ... combination of bevacizumab and chemotherapy has been shown ...
... study at the U.S. Department of Energy,s (DOE) ... vinyl-GABA, or GVG) blocks drug-seeking behavior in animals ... environment. Specifically, animals pre-treated with vigabatrin lost interest ... had previously been given methamphetamine. The results will ...
... of a metre in size are widely used, for ... also significant amounts of nanoparticles in exhaust emissions. However, ... because only a very small portion of research into ... Nanoparticles have even been dubbed the asbestos of the ...
... Medicare Advantage & Managed Medicaid, Bring,The SCOOTER Store ... Nov. 13 In a move,expanding its partnerships ... with 17 insurance companies that will allow nearly,seven ... mobility equipment,from The SCOOTER Store when power wheelchairs ...
Cached Medicine News:Health News:Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients 2Health News:Hope for treating relapse to methamphetamine abuse 2Health News:Hope for treating relapse to methamphetamine abuse 3Health News:Nanoparticles trigger cell death? 2Health News:The SCOOTER Store Expands Power Mobility Products, Services to 7 Million Health Plan Members 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: